UNSPSC 51142414: Sumatriptan

This classification denotes a serotonin agonist with the molecular formula C14H21N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8R78F6L9VO, chemically known as 1h-indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-n-methyl- but generally known as sumatriptan, which bears US NIH Compound Identifier 5358. European Medicines Agency schedules Sumatriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10770MIG.

UNSPSC 51142414 Sumatriptan is a Commodity code that nominally names a specific migraine medication, but recent state and local procurement activity under this code shows minimal alignment with the code's stated product. The three recent opportunities posted under this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS Commission), and generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). State and local governments are using this code designation inconsistently; the actual procurement spans emergency medical supplies, pharmacy benefit management strategy, and broad generic pharmaceutical supply contracts that do not center on sumatriptan or migraine-specific therapeutics. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. This code shows little relevant recent activity aligned to sumatriptan procurement specifically.

Geographic activity spans Florida, Texas, and Minnesota through the cooperative purchasing alliance, with secondary state and local participation. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The Texas HHS Commission issued a Request for Information (HHS0017013, posted April 3, 2026) on direct-to-manufacturer prescription capabilities to inform future pharmacy benefit program design. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. The code classification does not reflect the actual procurement scope, and buyers evaluating sumatriptan-specific opportunities should search outside this code designation or verify directly with issuing bodies.